Novel KRAS G12C and G12D inhibitors show early signs of activity in advanced solid tumours
As it emerges from some studies presented across different cancers, toxicity remains a major challenge
How therapeutically tractable is MUC1 as a tumour-associated antigen?
Early proof-of-concept is provided showing pan-tumour activity of a novel antibody–drug conjugate
Personalised cancer vaccines: the next frontier or an elusive goal?
Although genomics-guided personalised cancer vaccines have demonstrated efficacy in early-phase clinical studies, we are still awaiting the results of larger-scale trials
How connecting the dots could deliver a breakthrough in cancer vaccines
After decades of missed promises, cancer vaccines are likely approaching prime time due to major advances in cancer immunobiology, immunotherapy and biomedical technology
Is there a role for GLP-1 in the prevention and treatment of cancer?
Interest is growing rapidly in the field of oncology in the anti-obesity drug target that has recently been investigated in large retrospective studies and preclinical models
Harnessing Large Language Models in oncology: ESMO’s framework for integration in the clinic
The ELCAP statements, developed by a group of international experts, help oncology stakeholders recognise the opportunities and the risks of these artificial intelligence systems by categorising them into three types
Preventing cancer recurrence with novel antibody–drug conjugates
Presidential presentations in early breast cancer provide first evidence of ADCs rapidly moving into the curative setting across multiple cancer types
Trastuzumab deruxtecan is moving to the curative setting in early HER2-positive breast cancer
Positive findings from the DESTINY-Breast05 and DESTINY-Breast11 trials suggest that a paradigm change in the treatment of high-risk patients may be imminent
Is thymic health a novel tumour-agnostic biomarker?
Study findings reveal that good thymic health, based on an AI-derived algorithm, is associated with improved survival after immunotherapy in different tumour types
Head and neck cancers: should research continue to invest in immunotherapy?
Despite growing disappointing results from clinical trials, focus should now turn to the design of studies to better reflect tumour heterogeneity